Immune Design Corp. (NASDAQ:IMDZ)’s share price hit a new 52-week low on Tuesday . The company traded as low as $6.43 and last traded at $6.53, with a volume of 232,094 shares. The stock had previously closed at $7.01.

A number of equities analysts recently weighed in on the company. Cowen and Company reissued an “outperform” rating on shares of Immune Design Corp. in a research note on Wednesday, April 27th. Jefferies Group reissued a “buy” rating and issued a $20.00 price target on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Wells Fargo & Co. reissued a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Zacks Investment Research cut Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. Finally, Leerink Swann reissued a “buy” rating on shares of Immune Design Corp. in a research note on Thursday, May 12th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $24.00.

The firm’s market cap is $146.31 million. The firm’s 50-day moving average is $9.14 and its 200-day moving average is $11.60.

Immune Design Corp. (NASDAQ:IMDZ) last announced its earnings results on Tuesday, May 10th. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.01. Equities analysts forecast that Immune Design Corp. will post ($2.70) earnings per share for the current year.

Several institutional investors have recently modified their holdings of the stock. Jennison Associates raised its position in shares of Immune Design Corp. by 0.6% in the third quarter. Jennison Associates now owns 202,683 shares of the company’s stock valued at $2,473,000 after buying an additional 1,224 shares during the period. Oxford Asset Management purchased a new position in shares of Immune Design Corp. during the fourth quarter valued at about $1,166,000. Finally, Jennison Associates LLC raised its position in shares of Immune Design Corp. by 0.4% in the fourth quarter. Jennison Associates LLC now owns 203,452 shares of the company’s stock valued at $4,085,000 after buying an additional 769 shares during the period.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.